As doxycycline post-exposure prophylaxis (doxyPEP) for prevention of sexually transmitted infections (STIs) enters widespread use, questions remain about its implementation in the real world. At a symposium at the 13th International AIDS Society Conference on HIV Science (IAS 2025), experts discussed outstanding challenges, including increasing antibiotic resistance.
DoxyPEP involves taking a 200mg dose of the antibiotic doxycycline within 72 hours after sex. As reported in 2022, a study of men who have sex with men and transgender women in San Francisco and Seattle showed that doxyPEP significantly reduced the risk of chlamydia, syphilis and gonorrhoea. However, doxyPEP was less effective against gonorrhoea in French trials, likely because the background level of drug resistance is higher. A study of young cisgender women in Kenya found that doxyPEP was not effective, largely due to inconsistent use.
Read the full news story at aidsmap.
All aidsmap reports from IAS 2025 can be accessed here.
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.